The role of kidney in glucose homeostasis-SGLT2 inhibitors, a new approach in diabetes treatment

被引:17
作者
Andrianesis, Vasileios [1 ]
Doupis, John [1 ,2 ]
机构
[1] Salamis Naval Hosp, Dept Internal Med & Diabet, Salamis, Greece
[2] Iatriko P Falirou Med Ctr, Div Diabet, Athens, Greece
关键词
canagliflozin; dapagliflozin; glucosuria; renal gluconeogenesis; SGLT2 Na (+)/ D-glucose co-transporters; SGLT2; inhibitors; INADEQUATE GLYCEMIC CONTROL; AFFINITY NA+/GLUCOSE COTRANSPORTER; SELECTIVE SGLT2 INHIBITOR; PROXIMAL TUBULAR CELLS; DOUBLE-BLIND; RENAL GLUCOSURIA; REMOGLIFLOZIN ETABONATE; ADD-ON; SODIUM; DAPAGLIFLOZIN;
D O I
10.1586/17512433.2013.827399
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The role of the kidney in blood glucose-level regulation was until recently underestimated. Renal gluconeogenesis, renal glucose uptake and tubular glucose reabsorption are the three ways of renal involvement in glucose homeostasis. In the postabsorptive state, 20% of total glucose release is attributed to renal gluconeogenesis. Tubular glucose reabsorption is performed by the combined action of Na (+)/ D- glucose SGLTs co-transporters and GLUT-facilitated diffusion glucose transporters. SGLT2 inhibitors are a new family of agents, which occlude the path of SGLT2 glucose reabsorption and cause glucosuria. Efficacy of SGLT2 inhibitors includes reduction of HbA1c, fasting and postprandial blood glucose level and slight body weight and systolic blood pressure decrease. The most common adverse events of them are genital mycotic and urinary tract infections. Dapagliflozin and canagliflozin are the first agents of this class, approved from the European Medicine Agency and FDA, respectively.
引用
收藏
页码:519 / 539
页数:21
相关论文
共 99 条
[71]   Familial Renal Glucosuria and SGLT2: From a Mendelian Trait to a Therapeutic Target [J].
Santer, Rene ;
Calado, Joaquim .
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2010, 5 (01) :133-141
[72]   Long-term outcome of renal glucosuria type 0:: the original patient and his natural history [J].
Scholl-Bürgi, S ;
Santer, R ;
Ehrich, JHH .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2004, 19 (09) :2394-2396
[73]  
Schoolwerth A, 1988, MINER ELECTROLYTE ME, V14, P374
[74]  
Schultz S G., 1985, Physiology of Membrane Disorders, P283
[75]   Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise [J].
Stenlof, K. ;
Cefalu, W. T. ;
Kim, K. -A. ;
Alba, M. ;
Usiskin, K. ;
Tong, C. ;
Canovatchel, W. ;
Meininger, G. .
DIABETES OBESITY & METABOLISM, 2013, 15 (04) :372-382
[76]   Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial [J].
Strojek, K. ;
Yoon, K. H. ;
Hruba, V. ;
Elze, M. ;
Langkilde, A. M. ;
Parikh, S. .
DIABETES OBESITY & METABOLISM, 2011, 13 (10) :928-938
[77]   Effects of glucagon on renal and hepatic glutamine gluconeogenesis in normal postabsorptive humans [J].
Stumvoll, M ;
Meyer, C ;
Kreider, M ;
Perriello, G ;
Gerich, J .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1998, 47 (10) :1227-1232
[78]   UPTAKE AND RELEASE OF GLUCOSE BY THE HUMAN KIDNEY - POSTABSORPTIVE RATES AND RESPONSES TO EPINEPHRINE [J].
STUMVOLL, M ;
CHINTALAPUDI, U ;
PERRIELLO, G ;
WELLE, S ;
GUTIERREZ, O ;
GERICH, J .
JOURNAL OF CLINICAL INVESTIGATION, 1995, 96 (05) :2528-2533
[79]  
Trakatelis A., 2001, BIOCHEMISTRY 2, VA, P437
[80]   Molecular characterization of Vibrio parahaemolyticus vSGLT -: A model for sodium-coupled sugar cotransporters [J].
Turk, E ;
Kim, O ;
le Coutre, J ;
Whitelegge, JP ;
Eskandari, S ;
Lam, JT ;
Kreman, M ;
Zampighi, G ;
Faull, KF ;
Wright, EM .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (33) :25711-25716